Predicting differential rifamycin resistance in clinical Mycobacterium tuberculosis isolates by specific rpoB mutations

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 10, 2015, Pages 1222-1226

  ElMaraachli, W ^a   Slater, M ^b   Berrada, Z L ^c   Lin, S Y G ^c   Catanzaro, A ^a   Desmond, E ^c   Rodrigues, C ^d   Victor, T C ^e   Crudu, V ^f   Gler, M T ^g   Rodwell, T C ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^d P D HINDUJA NATIONAL HOSPITAL   (India)

^e STELLENBOSCH UNIVERSITY   (South Africa)

^f Microbiology and Morphology Laboratory   (Moldova)

^g MAKATI MEDICAL CENTER   (Philippines)

Author keywords

Diagnostics; MDR TB; Rifabutin; Rifampin

Indexed keywords

RIFABUTIN; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; BACTERIAL PROTEIN; DNA DIRECTED RNA POLYMERASE; RPOB PROTEIN, MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; CROSS RESISTANCE; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; RPOB GENE; DRUG EFFECTS; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; MUTATION; RETROSPECTIVE STUDY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTIBIOTICS, ANTITUBERCULAR; BACTERIAL PROTEINS; DNA-DIRECTED RNA POLYMERASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDIES; RIFABUTIN; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84942747360     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.14.0936     Document Type: Article

References (35)

1. Binda G, Domenichini E, Gottardi A, et al. Rifampicin, a general review. Arzneimittelforschung 1971; 21: 1907-1977.
2. Centers for Disease Control and Prevention. Treatment of tuberculosis. MMWR Morb Mortal Wkly Rep 2003; 52: 1-77.
3. th ed. WHO/HTM/TB/2009.420. Geneva, Switzerland: WHO, 2012. http://whqlibdoc.who.int/publications/2010/9789241547833-eng.pdf?ua1. Accessed July 2015.
4. Centers for Disease Control and Prevention. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR Morb Mortal Wkly Rep 2000; 49: 185-189.
5. Davies G, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev 2007; (4): CD005159.
6. World Health Organization. Global tuberculosis report, 2014. WHO/HTM/TB/2014.08. Geneva, Switzerland: WHO, 2014. http://www.who.int/tb/publications/global-report/en/. Accessed July 2015.
7. nd ed. San Francisco, CA, USA: Francis J. Curry National Tuberculosis Center, California Department of Public Health, 2011.
8. World Health Organization. WHO/HTM/TB/2010.3 Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva, Switzerland: WHO, 2010. http://whqlibdoc.who.int/publications/2010/9789241599191-eng.pdf. Accessed July 2015.
9. World Health Organization. Molecular line-probe assays for rapid screening of patients at risk of multi-drug resistant tuberculosis (MDR-TB): expert group report. Geneva, Switzerland: WHO, 2008.
10. Lin S Y, Rodwell T C, Victor T C, et al. Pyrosequencing for rapid detection of extensively drug-resistant Mycobacterium tuberculosis in clinical isolates and clinical specimens. J Clin Microbiol 2014; 52: 475-482.
11. Rodwell T C, Valafar F, Douglas J, et al. Predicting extensively drug-resistant tuberculosis (XDR-TB) phenotypes with genetic mutations. J Clin Microbiol 2014; 52: 781-789.
12. Ramaswamy S, Musser J M. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis. 1998 update. Tubercle Lung Dis 1998; 79: 3-29.
13. Jamieson F B, Guthrie J L, Neemuchwala A, Lastovetska O, Melano RG, Mehaffy C. Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis. J Clin Microbiol 2014; 52: 2157-2162.
14. Chen X, Kong F, Wang Q, Li C, Zhang J, Gilbert G L. Rapid detection of isoniazid, rifampin, and ofloxacin resistance in Mycobacterium tuberculosis clinical isolates using high-resolution melting analysis. J Clin Microbiol 2011; 49: 3450-3457.
15. Han X Q, Huang H R, Li Y J, et al. [Analysis of the antimycobacterial activities of rifabutin and the relationship between drug-resistance and rpoB mutations of Mycobacterium tuberculosis]. Zhonghua Jie He He Hu Xi Za Zhi 2011; 34: 762-765. [Chinese]
16. Chikamatsu K, Mizuno K, Yamada H, Mitarai S. [Cross-resistance between rifampicin and rifabutin among multi-drug resistant Mycobacterium tuberculosis strains]. Kekkaku 2009; 84: 631-633. [Japanese]
17. Cavusoglu C, Karaca-Derici Y, Bilgic A. In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Clin Microbiol Infect 2004; 10: 662-665.
18. Williams D L, Spring L, Collins L, et al. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42: 1853-1857.
19. Yang B, Koga H, Ohno H, et al. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J Antimicrob Chemother 1998; 42: 621-628.
20. Hillery N, Groessl E J, Trollip A, et al. The Global Consortium for Drug-resistant Tuberculosis Diagnostics (GCDD): design of a multi-site, head-to-head study of three rapid tests to detect extensively drug-resistant tuberculosis. Trials 2014; 15: 434.
21. World Health Organization. Use of liquid TB culture and drug susceptibility testing (DST) in low and medium income settings. Geneva, Switzerland: WHO, 2007. http://www.who.int/tb/laboratory/use-of-liquid-tb-culture-summary-report.pdf. Accessed July 2015.
22. nd ed. Approved Standard M24-A2. Wayne, PA, USA: CLSI, 2011.
23. Sintchenko V, Chew W K, Jelfs P J, Gilbert G L. Mutations in rpoB gene and rifabutin susceptibility of multidrug-resistant Mycobacterium tuberculosis strains isolated in Australia. Pathology (Phila) 1999; 31: 257-260.
24. Moghazeh S L, Pan X, Arain T, Stover C K, Musser J M, Kreiswirth B N. Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob Agents Chemother 1996; 40: 2655-2657.
25. Senol G, Erbaycu A, Ozsoz A. Incidence of cross resistance between rifampicin and rifabutin in Mycobacterium tuberculosis strains in Izmir, Turkey. J Chemother 2005; 17: 380-384.
26. Van Deun A, Barrera L, Bastian I, et al. Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. J Clin Microbiol 2009; 47: 3501-3506.
27. Van Deun A, Aung K J, Bola V, et al. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 2013; 51: 2633-2640.
28. Rigouts L, Gumusboga M, de Rijk W B, et al. Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. J Clin Microbiol 2013; 51: 2641-2645.
29. Gillespie S H, Baskerville A J, Davidson R N, Felmingham D, Bryceson A D. The serum rifabutin concentrations in a patient successfully treated for multi-resistant Mycobacterium tuberculosis infection. J Antimicrob Chemother 1990; 25: 490-491.
30. Pretet S, Lebeaut A, Parrot R, Truffot C, Grosset J, Dinh-Xuan AT. Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. G.E.T.I.M. (Group for the Study and Treatment of Resistant Mycobacterial Infection). Eur Respir J 1992; 5: 680-684.
31. Jo KW, Ji W, Hong Y, et al. The efficacy of rifabutin for rifabutin-susceptible, multidrug-resistant tuberculosis. Respir Med 2013; 107: 292-297.
32. Schon T, Jureen P, Chryssanthou E, et al. Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact? J Antimicrob Chemother 2013; 68: 2074-2077.
33. Uzun M, Erturan Z, Ang O. Investigation of cross-resistance between rifampin and rifabutin in Mycobacterium tuberculosis complex strains. Int J Tuberc Lung Dis 2002; 6: 164-165.
34. Dickinson J M, Mitchison D A. In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle 1987; 68: 177-182.
35. Yoshida S, Suzuki K, Iwamoto T, et al. Comparison of rifabutin susceptibility and rpoB mutations in multi-drug-resistant Mycobacterium tuberculosis strains by DNA sequencing and the line probe assay. J Infect Chemother 2010; 16: 360-363.